JNJ 39758979

Drug Profile

JNJ 39758979

Alternative Names: JNJ-39758979

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antiasthmatics; Antipruritics; Antirheumatics; Pyrimidines; Pyrrolidines; Skin disorder therapies
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Atopic dermatitis; Rheumatoid arthritis

Most Recent Events

  • 11 May 2012 Johnson & Johnson withdraws a phase II trial in Asthma prior to enrolment (NCT01493882)
  • 13 Jan 2012 Johnson & Johnson suspends a phase II trial in Rheumatoid arthritis in US (NCT01480388)
  • 01 Dec 2011 Johnson & Johnson completes a phase I for Rheumatoid arthritis (combination therapy) in Germany and USA (NCT01442545)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top